首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Expert Review Of Pharmacoeconomics & Outcomes Research

Expert Review Of Pharmacoeconomics & Outcomes Research杂志,由Taylor and Francis Ltd.出版,于2001年创刊,6 issues/year,出版语言English,ISSN:1473-7167,E-ISSN:1744-8379。

投稿咨询
Expert Review Of Pharmacoeconomics & Outcomes Research
Expert Review Of Pharmacoeconomics & Outcomes Research
Expert Review Of Pharmacoeconomics & Outcomes Research
SCI SCIE SSCI

杂志介绍

JCR分区
Q3
中科院分区
4区
影响因子
2.2
CiteScore
3.4
期刊收录
SCI、SCIE、SSCI

Expert Review Of Pharmacoeconomics & Outcomes Research(中文译名:《药物经济学和结果研究专家评论》),ISSN:1473-7167,EISSN:1744-8379,是Taylor and Francis Ltd.出版的国际性学术期刊,创刊于2001年,以6 issues/year形式稳定发行,2026年总发文量约121篇。该刊采用非OA开放访问,学科归属为HEALTH CARE SCIENCES & SERVICES - PHARMACOLOGY & PHARMACY。该刊是医学、卫生保健与服务领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)、SSCI(社会科学引文索引)等国际主流学术数据库收录。2026年期刊影响因子达2.2,2025年期刊CiteScore为3.4,2025年期刊自引率约4.5%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Expert Review Of Pharmacoeconomics & Outcomes Research长期聚焦医学、卫生保健与服务及相关产业的技术应用前沿,平均审稿周期较慢,6-12周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、卫生保健与服务领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、Netherlands、GERMANY (FED REP GER)、Spain、France、Italy等为核心发文国家与地区;KAROLINSKA INSTITUTETMAASTRICHT UNIVERSITY、SYREON RES INST、UNIVERSITY OF GRONINGEN、TRIMBOS INSTITUTE、UNIVERSITY OF BARCELONA、EOTVOS LORAND UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务 HEALTH POLICY & SERVICES 卫生政策与服务 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务 HEALTH POLICY & SERVICES 卫生政策与服务 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务 HEALTH POLICY & SERVICES 卫生政策与服务 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEALTH CARE SCIENCES & SERVICES SCIE Q3 111 / 194

43

学科:HEALTH POLICY & SERVICES SSCI Q3 67 / 125

46.8

学科:PHARMACOLOGY & PHARMACY SCIE Q3 231 / 356

35.3

学科:HEALTH CARE SCIENCES & SERVICES SCIE Q3 141 / 194

27.58

学科:HEALTH POLICY & SERVICES SSCI Q4 100 / 125

20.4

学科:PHARMACOLOGY & PHARMACY SCIE Q3 227 / 356

36.38

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEALTH CARE SCIENCES & SERVICES SCIE Q3 100 / 174

42.8

学科:HEALTH POLICY & SERVICES SSCI Q3 72 / 118

39.4

学科:PHARMACOLOGY & PHARMACY SCIE Q3 240 / 354

32.3

学科:HEALTH CARE SCIENCES & SERVICES SCIE Q3 112 / 175

36.29

学科:HEALTH POLICY & SERVICES SSCI Q3 83 / 119

30.67

学科:PHARMACOLOGY & PHARMACY SCIE Q3 210 / 354

40.82


中国学者近期发文

1
Physicians' preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in Chin

Author:Li, Yan; Du, Junni; Tian, Chenhui; Ma, Aixia; Tao, Tiantian; Chen, Pingyu

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2650162

2
Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cance

Author:Kou, Conghui; Wu, Huina; Liu, Lihui; Zhao, Xifeng; Nie, Jing

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2626573

3
Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cance

Author:Liu, Tong; Yao, Yao; Liu, Bingjie; Teng, Xue; Dong, Mei; Zhang, Xin

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2509706

4
Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the US

Author:Liu, Tong; Yao, Yao; Teng, Xue; Tong, Zhiqiang; Dong, Mei; Yao, Ruihong

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2521444

5
Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12

Author:Yao, Ruihong; Yao, Yao; Teng, Xue; Jin, Yao; Guan, Shangwei; Dong, Mei; Liu, Tong

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2521439

6
Cost-effectiveness analysis of Risdiplam and Nusinersen for the treatment of Chinese patients with spinal muscular atroph

Author:Huang, Yueyang; Yuan, Hongmei; Huang, Zhe

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2499720

7
Impact of moderate and severe exacerbations on clinical prognosis and economic burden of chronic obstructive pulmonary disease in Chin

Author:Gan, Lei; He, Xiaoning; Wu, Jing

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2507425

8
Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in Chin

Author:Zhao, Shan; Kang, Shuo

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2483423

9
Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysi

Author:Wu, Weijia; Wang, Yannan; Lou, Yingting; Fan, Xiaoyuan; Yang, Wenqianzi; Tang, Fengyuan; Zhao, Zixuan; Dong, Hengjin

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2461636

10
Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysi

Author:Xie, Ouyang; Wu, Meiyu; Li, Andong; Meng, Kehui; Xiang, Heng; Tan, Chongqing; Peng, Liubao; Ge, Yan; Wan, Xiaomin

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2451740


在线咨询

Expert Review Of Pharmacoeconomics & Outcomes Research

国际简称:EXPERT REV PHARM OUT参考译名:药物经济学和结果研究专家评论

年发文量:121 CiteScore:3.4 是否预警:否 Gold OA文章占比:11.59% 研究类文章占比:71.07%

杂志社联系方式:2-4 PARK SQUARE, MILTON PARK, ABINGDON, England, OXON, OX14 4RN

Expert Review Of Pharmacoeconomics & Outcomes Research